A Phase Ib, Open-label, Dose-finding Study of the JAK Inhibitor INC424 Tablets Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-polycythemia Veramyelofibrosis (PPV-MF) or Post-essentialthrombocythemia-myelofibrosis (PET-MF) and Baseline Platelet Counts ≥50 x109/L and <100 x109/L (EXPAND)
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Acronyms EXPAND
- Sponsors Incyte Corporation; Novartis
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 02 Oct 2020 Status changed from active, no longer recruiting to completed.
- 04 Jul 2018 Results of the 48 week observation period published in the Media Release